Challenges such as lack of predictive biomarkers, due to the intricacies of signaling pathways in ER+/HER2- BC, and significant adverse events due to off-target toxicities, have hindered the success of FGFR-targeted therapies in BC (109). Here, ERBB2 is linked to breast cancer.